I-MAB (NAS:IMAB)
$ 1.055 -0.04 (-3.64%) Market Cap: 81.84 Mil Enterprise Value: -118.19 Mil PE Ratio: 0 PB Ratio: 0.35 GF Score: 35/100

Full Year 2021 I-Mab Earnings Call Transcript

Mar 29, 2022 / 12:00PM GMT
Release Date Price: $19.39 (+15.07%)
Tyler Ehler

Allow me to welcome you all to the I-Mab Biopharma Full Year 2021 Financial Results and Business Update Conference Call. This is Tyler Ehler here, I-Mab's Senior Director of Investor Relations. (Operator Instructions) Later, we will conduct a Q&A session and instructions will follow at that time.

Earlier today, we issued a press release providing a review of our financial results for the full year ended December 31, 2021, as well as an overview of our recent corporate highlights and upcoming milestones. The press release can be accessed on the Investors portion of our website at ir.i-mabbiopharma.com.

Joining me today on the call from I-Mab's senior management team are Dr. Jingwu Zang, our Founder Chairman and Acting CEO of I-Mab; Dr. Andrew Zhu, our President of I-Mab; Mr. John Long, CFO of I-Mab; and Mr. Jielun Zhu, Chief Strategy Officer of I-Mab.

Dr. Zang will start by providing a high-level overview of our recent achievements and upcoming milestones, followed by Dr. Andrew Zhu, who will provide an update on our R&D progress; and Mr. Zhu, who will provide an

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot